Home | Cancers | Prostate Cancer

Prostate Cancer

Chronic Inflammation Linked to High-Grade Prostate Cancer

Men who show signs of chronic inflammation in non-cancerous prostate tissue may have nearly twice the risk of actually having prostate cancer ...

Chronic Inflammation May Be Linked to Aggressive Prostate Cancer

PHILADELPHIA — The presence of chronic inflammation in benign prostate tissue was associated with high-grade, or aggressive, prostate cancer, and this association ...

Cholesterol unlocks clues to prostate cancer Survival hope for melanoma patients thanks to new vaccine

University of Adelaide researchers have discovered that a new trial vaccine offers the most promising treatment to date for melanoma that has spread, with increased patient survival rates and improved ability to stop or reverse the cancer. ... Full story

Cholesterol unlocks clues to prostate cancer spread

Scientists have uncovered a link between cholesterol and prostate cancer’s ability to spread to the bones in a study published in the British Journal of Cancer today. ... Full story

Study finds prostate cancer tests underestimate disease in half of cases

Tests to grade and stage prostate cancer underestimated the severity of the disease in half of men whose cancers would have been classified as ‘slow growing’ in a study* published in the British Journal of Cancer. ... Full story

Circumcision could prevent prostate cancer... if it's performed after the age of 35

Researchers at the University of Montreal and the INRS-Institut-Armand-Frappier have shown that men circumcised after the age of 35 were 45% less at risk of later developing prostate cancer than uncircumcised men. This is one of the findings that resulted from a study undertaken by Andrea Spence and her research directors Marie-Élise Parent and Marie-Claude Rousseau. The researchers interviewed 2114 men living on the Island of Montreal. ... Full story

Blood-based Biomarker May Identify Prostate Cancers That Will Be Resistant to Enzalutamide

by AACR Communications Staff - SAN DIEGO — Men with metastatic, castration-resistant prostate cancer who started treatment with the drug enzalutamide (Xtandi) and had a molecule called AR-V7 present in circulating tumor cells (CTCs) obtained prior to treatment had a worse response to enzalutamide compared with those who had no detectable AR-V7, according to results presented here at the AACR Annual Meeting 2014, April 5-9. ... Full story

Dose-escalated hypofractionated IMRT for localized prostate cancer has similar side effects when compared to conventional IMRT

Dose-escalated intensity modulated radiation therapy (IMRT) with use of a moderate hypofractionation regimen (72 Gy in 2.4 Gy fractions) can safely treat patients with localized prostate cancer with limited grade 2 or 3 late toxicity, according to a study published in the April 1, 2014 edition of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO). ... Full story

Minority disparities evident in prostate cancer survival rate, Mayo Clinic study shows

PHOENIX — A Mayo Clinic study reviewed data on more than 290,000 men with prostate cancer from the past 20 years and found that African-American men are at increased risk for poorer survival rate following prostate cancer treatment compared to other minority groups. ... Full story

Circulating tumor cells may be better predictor of prostate cancer survival

By Leslie Ridgeway - New research by USC Norris Comprehensive Cancer Center scientists demonstrated that measuring circulating tumor cells (CTCs) — the cells that spread cancer through the body — may be a better predictor of patient survival than the prostate specific antigen (PSA). ... Full story

1 2 3 4 5 6 7 8 9 10 next total: 95 | displaying: 1 - 10